Revolution Medicines to Present New Preclinical Data from RAS(ON) Inhibitor Programs at AACR-NCI-EORTC Virtual International Conference on Molecular Targets
REDWOOD CITY, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that new preclinical data from several of the company’s RAS(ON) inhibitor programs will be reported in an invited oral presentation during a plenary session of the upcoming AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics being held October 7-10, 2021.
Details of the upcoming oral presentation at the AACR-NCI-EORTC conference are as follows:
- Title: Discovery and Development of RAS(ON) Inhibitors Beyond KRASG12C
- Presenter: Steve Kelsey, M.D., president, research and development
- Session: Plenary Session 5: Drugging Difficult Targets
- Session Date/Time: Saturday, October 9, 2021, 12:05 – 1:55 p.m. Eastern
- Session Panel Discussion: To follow completion of Plenary Session 5 presentations
To access a copy of the presentation slides, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations. The presentation slides will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.
Additional information on the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutic is available through the conference website at https://www.aacr.org/meeting/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics/
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.
The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6291, RMC-6236, and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in development include RMC-4630, RMC-5552, and RMC-5845.
Contacts: For Investors: Vida Strategic Partners Stephanie Diaz 415-675-7401 sdiaz@vidasp.com For Media: Vida Strategic Partners Tim Brons 415-675-7402 tbrons@vidasp.com
